Sunshine Biopharma Stock Current Asset
| SBFM Stock | USD 2.36 0.24 11.32% |
Sunshine Biopharma fundamentals help investors to digest information that contributes to Sunshine Biopharma's financial success or failures. It also enables traders to predict the movement of Sunshine Stock. The fundamental analysis module provides a way to measure Sunshine Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sunshine Biopharma stock.
As of the 23rd of November 2024, Total Current Assets is likely to grow to about 26.1 M. Also, Other Current Assets is likely to grow to about 326.1 K. Sunshine | Current Asset |
Sunshine Biopharma Company Current Asset Analysis
Sunshine Biopharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Sunshine Biopharma Current Asset | 23 K |
Most of Sunshine Biopharma's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunshine Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sunshine Current Asset Historical Pattern
Today, most investors in Sunshine Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sunshine Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sunshine Biopharma current asset as a starting point in their analysis.
Sunshine Biopharma Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Sunshine Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Sunshine Biopharma has a Current Asset of 23 K. This is 100.0% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Sunshine Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sunshine Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sunshine Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Sunshine Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | (7.4 M) | ||||
| Shares Outstanding | 2 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 1.84 % | ||||
| Number Of Shares Shorted | 374.13 K | ||||
| Price To Earning | 1.07 X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.13 X | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 1.7 M | ||||
| EBITDA | (3.82 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 41.74 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 657.71 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 401.11 X | ||||
| Book Value Per Share | 12.52 X | ||||
| Cash Flow From Operations | (8.78 M) | ||||
| Short Ratio | 4.13 X | ||||
| Earnings Per Share | (127.90) X | ||||
| Target Price | 300.0 | ||||
| Number Of Employees | 44 | ||||
| Beta | -1.04 | ||||
| Market Capitalization | 4.24 M | ||||
| Total Asset | 27.35 M | ||||
| Retained Earnings | (63.91 M) | ||||
| Working Capital | 19.34 M | ||||
| Current Asset | 23 K | ||||
| Current Liabilities | 277 K | ||||
| Net Asset | 27.35 M |
About Sunshine Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Sunshine Biopharma Piotroski F Score and Sunshine Biopharma Altman Z Score analysis. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.